Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. FLGT
stocks logo

FLGT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
85.38M
+12.03%
0.030
-25.43%
82.38M
+12.14%
-0.114
-386.08%
89.34M
+9.21%
-0.077
-209.33%
Estimates Revision
The market is revising Upward the revenue expectations for Fulgent Genetics, Inc. (FLGT) for FY2025, with the revenue forecasts being adjusted by 1.43% over the past three months. During the same period, the stock price has changed by 28.93%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.43%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-180.69%
In Past 3 Month
Stock Price
Go Up
up Image
+28.93%
In Past 3 Month
Wall Street analysts forecast FLGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FLGT is 32.50 USD with a low forecast of 30.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FLGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FLGT is 32.50 USD with a low forecast of 30.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 28.300
sliders
Low
30.00
Averages
32.50
High
35.00
Current: 28.300
sliders
Low
30.00
Averages
32.50
High
35.00
Piper Sandler
Neutral
maintain
$21 -> $30
2025-11-11
Reason
Piper Sandler
Price Target
$21 -> $30
2025-11-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Fulgent Genetics to $30 from $21 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
UBS
Neutral -> Buy
upgrade
$20 -> $30
2025-08-05
Reason
UBS
Price Target
$20 -> $30
2025-08-05
upgrade
Neutral -> Buy
Reason
UBS upgraded Fulgent Genetics to Buy from Neutral with a price target of $30, up from $20, after assuming coverage of the name. The firm sees potential for upside in the company's Precision Diagnostics unit, which represents 60% of total sales, due to share gain opportunities and a more favorable reimbursement landscape. In addition, Fulgent's Anatomic Pathology segment has started to recover and is no longer dilutive to growth, the analyst tells investors in a research note. UBS sees the company sustaining 10% revenue growth in 2025 and beyond.
Piper Sandler
Neutral
downgrade
$23 -> $21
2025-08-04
Reason
Piper Sandler
Price Target
$23 -> $21
2025-08-04
downgrade
Neutral
Reason
Piper Sandler lowered the firm's price target on Fulgent Genetics to $21 from $23 following quarterly results. The firm keeps a Neutral rating on the shares.
Piper Sandler
David Westenberg
Hold
Maintains
$22 → $16
2025-03-04
Reason
Piper Sandler
David Westenberg
Price Target
$22 → $16
2025-03-04
Maintains
Hold
Reason
Piper Sandler analyst David Westenberg lowered the firm's price target on Fulgent Genetics to $16 from $22 following quarterly results. The firm keeps a Neutral rating on the shares.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Fulgent Genetics Inc (FLGT.O) is -128.81, compared to its 5-year average forward P/E of -34.80. For a more detailed relative valuation and DCF analysis to assess Fulgent Genetics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-34.80
Current PE
-128.81
Overvalued PE
39.39
Undervalued PE
-108.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
7.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
18.30
Undervalued EV/EBITDA
-3.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.16
Current PS
0.00
Overvalued PS
4.28
Undervalued PS
2.04
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 169.46% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

FLGT News & Events

Events Timeline

(ET)
2025-11-07
07:20:02
Fulgent Genetics increases FY25 EPS forecast to 30c, up from (35c), matching consensus of (35c)
select
2025-11-07
07:17:19
Fulgent Genetics announces Q3 earnings per share of 21 cents, falling short of the expected 22 cents.
select
2025-10-20 (ET)
2025-10-20
06:07:05
Fulgent Genetics Reveals Initial Findings from Phase 2 Trial of FID-007
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
Transcript of Fulgent Genetics (FLGT) Earnings Call
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
7.0
11-07SeekingAlpha
Fulgent Genetics increases 2025 revenue forecast to $325M fueled by new product growth

  • Management Insights: CEO Ming Hsieh reported sustained business momentum in Q3 2025, with growth in laboratory services driven by AI investments and an advancing therapeutic pipeline, including promising results from Phase II trials of FID-007 for head and neck cancer.

  • Financial Performance: Fulgent Genetics achieved $84.1 million in revenue for Q3, with improved gross margins and a reduced GAAP loss of $6.6 million, while also raising its full-year revenue outlook to $325 million and revising EPS guidance positively.

  • Product Innovations: The company launched an ultrarapid whole genome sequencing service and expanded its Beacon carrier screening panel, enhancing its capabilities in detecting rare genetic conditions and positioning itself competitively in the market.

  • Outlook and Risks: Management expressed confidence in operational efficiencies and growth prospects, despite acknowledging risks related to billing software changes and the adoption of new products, while monitoring payer reimbursement dynamics and clinical trial costs.

[object Object]
Preview
8.0
11-07TipRanks
Today's Options Volatility and Implied Earnings Changes - November 07, 2025

  • Earnings Reports: Major companies such as Brookfield Infrastructure, Enbridge, and Wendy's are set to report earnings today, with expected stock movements based on options prices.

  • Options Activity: Investors are closely monitoring options activity prior to earnings announcements to gauge potential stock price movements.

  • Implied Moves: A list of companies reporting earnings includes their expected stock price changes, with notable movements for Canopy Growth (+13.76%) and Algonquin Power (+17.48%).

  • Trading Risks: The article emphasizes the risks associated with options trading and advises thorough research before participating.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Fulgent Genetics Inc (FLGT) stock price today?

The current price of FLGT is 28.3 USD — it has decreased -0.63 % in the last trading day.

arrow icon

What is Fulgent Genetics Inc (FLGT)'s business?

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

arrow icon

What is the price predicton of FLGT Stock?

Wall Street analysts forecast FLGT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FLGT is 32.50 USD with a low forecast of 30.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Fulgent Genetics Inc (FLGT)'s revenue for the last quarter?

Fulgent Genetics Inc revenue for the last quarter amounts to 84.07M USD, increased 17.18 % YoY.

arrow icon

What is Fulgent Genetics Inc (FLGT)'s earnings per share (EPS) for the last quarter?

Fulgent Genetics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -56.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Fulgent Genetics Inc (FLGT)'s fundamentals?

The market is revising Upward the revenue expectations for Fulgent Genetics, Inc. (FLGT) for FY2025, with the revenue forecasts being adjusted by 1.43% over the past three months. During the same period, the stock price has changed by 28.93%.
arrow icon

How many employees does Fulgent Genetics Inc (FLGT). have?

Fulgent Genetics Inc (FLGT) has 1313 emplpoyees as of December 05 2025.

arrow icon

What is Fulgent Genetics Inc (FLGT) market cap?

Today FLGT has the market capitalization of 874.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free